MFN. IRA. European HTA reform. The rules for US companies accessing global markets are being rewritten. Every pricing decision made abroad now flows back to your US reimbursement. 130+ manufacturers trust JSC to navigate what's next and protect their pricing, reimbursement and launch timelines.
Our team replies within 24 hours. No commitment.
Through executive orders, CMS mandatory models and tariff-linked enforcement, the US government has created a structural link between what manufacturers charge abroad and what they receive domestically. Every list price decision in a reference country now carries direct, measurable consequences for US revenue.
Mandatory international price benchmarking for high-cost, single-source drugs in oncology, rheumatology, immunology, ophthalmology and endocrinology. Net prices benchmarked against 19 OECD reference countries.
Extends international price benchmarking to retail and specialty pharmacy drugs across six therapeutic categories, including cardiovascular, immunological and metabolic treatments.
Voluntary supplemental rebates aligning Medicaid net prices with the second-lowest net price across 8 reference countries (G7 + Denmark), adjusted by GDP per capita.
We partner with pharma, biotech, medtech and digital health companies to protect pricing, secure reimbursement and de-risk launches across the US and European markets.
We model your global pricing corridor across the 19 MFN reference countries, stress-test launch sequencing, and build pricing strategies that protect US reimbursement while securing European access, before your first launch.
We build country-specific dossiers for G-BA, HAS, NICE, AIFA and AEMPS. Tailoring value propositions, economic models and evidence packages to match each payer's criteria and the pricing ambition each market can sustain.
We support direct engagement with European payers and HTA bodies: early scientific advice, negotiation preparation, and post-launch price defense, so your launch assumptions meet real-world payer expectations.
JSC supports US manufacturers across the American, European and international markets, with on-the-ground expertise in every major MFN reference country.
"Their expertise and ease of communication have greatly enriched our projects. The team has deep knowledge of EU HTA processes, making them an invaluable asset for navigating complex reimbursement environments."
"A company and team with real, hands-on experience developing market access strategies in pharma. Justin Stindt Consulting consistently delivers high-quality work that stands up in the real, complex world of market access."
"JSC is a specialized consultancy that combines technical mastery, real-world experience and the ability to adapt its services to the client's needs."
Our senior team replies within 24 hours. No commitment. Whether you are two years out from launch or already in-market, we will help you pressure-test your global pricing and market access strategy under the new MFN reality.
Response within 24h — No commitment.